Stockscreener 앱 받기
71.91
0.53%
-0.385
전일 마감가:
$72.29
열려 있는:
$72.585
하루 거래량:
466.33K
Relative Volume:
0.48
시가총액:
$3.36B
수익:
$535.08M
순이익/손실:
$-48.27M
주가수익비율:
-63.44
EPS:
-1.1335
순현금흐름:
$-31.54M
1주 성능:
-0.44%
1개월 성능:
-8.09%
6개월 성능:
+0.15%
1년 성능:
-4.06%
1일 변동 폭
$71.72
$74.94
1주일 범위
$70.03
$76.64
52주 변동 폭
$53.89
$91.53
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
명칭
Tarsus Pharmaceuticals Inc
전화
(949) 409-9820
주소
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
71.91 | 3.36B | 535.08M | -48.27M | -31.54M | -1.1335 |
VRTX
Vertex Pharmaceuticals Inc
|
510.27 | 129.33B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
237.88 | 94.97B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
801.50 | 82.52B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
849.70 | 53.43B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
372.00 | 42.08B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-09-24 | 재개 | Goldman | Buy |
| 2026-09-16 | 재개 | Barclays | Overweight |
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-11-20 | 개시 | Mizuho | Outperform |
| 2025-06-02 | 재개 | Oppenheimer | Outperform |
| 2025-05-27 | 재개 | H.C. Wainwright | Buy |
| 2023-11-20 | 개시 | Goldman | Neutral |
| 2023-07-18 | 개시 | William Blair | Outperform |
| 2023-05-18 | 개시 | Guggenheim | Buy |
| 2022-08-01 | 개시 | Barclays | Overweight |
| 2021-12-21 | 개시 | H.C. Wainwright | Buy |
| 2021-11-23 | 개시 | Oppenheimer | Outperform |
| 2020-11-10 | 개시 | BofA Securities | Buy |
| 2020-11-10 | 개시 | Jefferies | Buy |
| 2020-11-10 | 개시 | Ladenburg Thalmann | Buy |
| 2020-11-10 | 개시 | Raymond James | Strong Buy |
모두보기
Tarsus Pharmaceuticals Inc 주식(TARS)의 최신 뉴스
Tarsus Pharmaceuticals (TARS) director adds 201 shares through RSU conversion - Stock Titan
Tarsus Pharmaceuticals (TARS) director sells shares under preset plan - Stock Titan
Nearly $1M Tarsus (NASDAQ: TARS) insider share sale planned by a company director - Stock Titan
Tarsus Pharmaceuticals (NASDAQ: TARS) Acquires Alkeus, Potential $350M Milestone Payments Included - Kalkine Media
Tarsus Pharmaceuticals Finalizes Acquisition of Alkeus Pharmaceuticals with $270M Cash and Stock Deal - Kalkine Media
Tarsus Pharmaceuticals COO Neervannan Seshadri Offloads 4,564 Shares at $85 Each (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals CEO Bobak Azamian Executes Open-Market Sale of 10,000 Shares at $90.27-$91.27 (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals CMO Executes Stock Sales Under Dual 10b5-1 Trading Plans - Kalkine Media
Tarsus (NASDAQ: TARS) CEO sells 10,000 shares under 10b5-1 plan - Stock Titan
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals gains analyst boost afte... - Pluang
TARS Maintains by Jefferies -- Price Target Raised to $105 - GuruFocus
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com Canada
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com India
Jefferies raises Tarsus Pharmaceuticals price target on guidance By Investing.com - Investing.com UK
Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline - VisionMonday.com
Tarsus Finalizes Alkeus Acquisition, Expanding Eyecare Pipeline - visionmonday.com
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com South Africa
Officer at Tarsus (NASDAQ: TARS) lines up six-figure stock sale - Stock Titan
After recent sales, Tarsus (NASDAQ: TARS) officer's spouse plans another stock trade - Stock Titan
About $943K in stock set for sale at Tarsus (TARS) - Stock Titan
Planned Tarsus (TARS) officer sale covers 4,564 shares - Stock Titan
Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition - marketscreener.com
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com Nigeria
Tarsus Pharmaceuticals CEO Bobak R. Azamian Offloads 10,000 Shares at $80.06 Each (NASDAQ: TARS) - Kalkine Media
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com Australia
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD - investing.com
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD - Investing.com India
Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD By Investing.com - Investing.com Canada
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care - manilatimes.net
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care - GlobeNewswire
A potentially blinding eye disease has no FDA-approved therapy. Tarsus bought a company developing one. - Stock Titan
Tarsus Pharmaceuticals (TARS) CEO sells 10,000 shares in plan trade - Stock Titan
Shareholder plans new stock sale at Tarsus (NASDAQ: TARS) - Stock Titan
Former Tarsus (NASDAQ: TARS) officer plans another stock sale - Stock Titan
Tarsus (NASDAQ: TARS) exec plans $431K sale after recent $340K stock cash-out - Stock Titan
Tarsus (NASDAQ: TARS) officer lines up another stock sale - Stock Titan
Tarsus to Participate in Upcoming Investor Conferences - manilatimes.net
Tarsus to Participate in Upcoming Investor Conferences - Yahoo Finance
Ex-officer lines up third multimillion sale in Tarsus (NASDAQ: TARS) stock - Stock Titan
Planned $340K insider stock sale at Tarsus (NASDAQ: TARS) from vested pay - Stock Titan
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 5.75 Million in Common Stocks - Moomoo
After $3.8M sale, Tarsus (TARS) ex-officer plans more selling - Stock Titan
Tarsus (TARS) Technicals: Finishes 1.69% Up at $72.70 in the Latest Session; Next Test: Support at $69.06 and Resistance at $76.34 Frame the Range in Latest TradingVWAP Bounce - vinanet.vn
Tarsus (NASDAQ: TARS) ex-officer plans sale of 53K shares - Stock Titan
Form 144 | Tarsus Pharmaceuticals(TARS.US) Insider Proposes to Sell 3.82 Million in Common Stocks - Moomoo
TimesSquare Capital Management LLC Takes $23.25 Million Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales GuidanceAnd What's Next - Sahm
Tarsus Pharmaceuticals (TARS) Shares Just Moved, What Is Behind The Attention? - Sahm
Why Tarsus Pharmaceuticals (TARS) Is Up 6.8% After Raising XDEMVY 2026 Sales GuidanceAnd What's Next - simplywall.st
Tarsus Pharmaceuticals Inc (TARS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tarsus Pharmaceuticals Inc 주식 (TARS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| WILLIAM J LINK | DIRECTOR |
Sep 15 '26 |
Proposed Sale |
78.38 |
12,500 |
979,745 |
0 |
| Lin Elizabeth Yeu | Chief Medical Officer |
Sep 04 '26 |
Sale |
87.50 |
10,773 |
942,635 |
2,547 |
| Lin Elizabeth Yeu | Chief Medical Officer |
Sep 04 '26 |
Sale |
87.50 |
3,180 |
278,250 |
1,590 |
| Neervannan Seshadri | Chief Operating Officer |
Sep 04 '26 |
Sale |
85.00 |
4,564 |
387,940 |
78,532 |
| BOBAK AZAMIAN | OFFICER |
Sep 04 '26 |
Proposed Sale |
90.56 |
10,000 |
905,587 |
0 |
| Lin Elizabeth Yeu | Member of immediate family of |
Sep 04 '26 |
Proposed Sale |
87.50 |
3,180 |
278,250 |
0 |
| Lin Elizabeth Yeu | Officer |
Sep 04 '26 |
Proposed Sale |
87.50 |
10,773 |
942,635 |
0 |
| Azamian Bobak R. | President/CEO and Board Chair |
Sep 04 '26 |
Sale |
90.56 |
10,000 |
905,600 |
827,991 |
| Neervannan Seshadri | Officer |
Sep 04 '26 |
Proposed Sale |
85.00 |
4,564 |
387,940 |
0 |
| BOBAK AZAMIAN | OFFICER |
Sep 02 '26 |
Proposed Sale |
80.06 |
10,000 |
800,569 |
0 |
1.58%
0.31%
자본화:
|
볼륨(24시간):